NCT04414163

A Study of IMC-001 in Subjects With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal Type

An Open-label, Single-arm, Phase 2 Study to Investigate the Efficacy and Safety of IMC-001 in Patients With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal Type

• Status: Active Not Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 23 (actual)
• Sponsor: ImmuneOncia Therapeutics Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a phase 2, Open-label, to investigate the efficacy and safety of IMC-001 in patients with Relapsed or Refractory extranodal NK/T cell lymphoma, nasal type

Detailed description

IMC-001 is a PD-L1 targeting, fully human monoclonal antibody. The purpose of this study is to determine and evaluate the efficacy and safety of IMC-001. 20mg/kg every 2 weeks, IV infusion of IMC-001 will be tested in subjects with Relapsed or Refractory extranodal NK/T cell lymphoma, nasal type.

Conditions

• Extranodal NK/T-cell Lymphoma, Nasal Type
• Extranodal NK/T-cell Lymphoma

Interventions

Type	Name	Description
DRUG	IMC-001	Single dose level for enrollment subject (IMC-001 20mg/kg every 2 weeks)

Timeline

• Start date: 2020-10-27
• Primary completion: 2024-07-30
• Completion: 2026-02-28
• First posted: 2020-06-04
• Last updated: 2025-06-18

Locations

5 sites across 1 country: South Korea